MOVe-NOW will build on existing LAGEVRIO data to assess efficacy in the current COVID-19 environment and support applications for licensure The MOVe-NOW study will use a different formulation of ...

The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

As coronavirus concerns increase with the changing of the seasons, the most commonly used oral antiviral treatments are in the spotlight once again. Lagevrio acts by introducing mutations, destroying ...

(The Hill) – A new study published Monday links COVID-19 antiviral created by Merck and new mutations of the virus that have been sequenced around the world. Molnupiravir, known commercially as ...

With every new infection, the pandemic coronavirus gets new chances to mutate and adapt, creating opportunities for the virus to evolve new variants that are better at dodging our immune systems and ...

Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir. Merck said Monday it is seeking US Food and ...

Kenilworth-based Merck is asking the U.S. Food and Drug Administration for emergency approval of a COVID-19 antiviral pill after trials for the drug showed promising results, the company announced Oct ...

The world could soon be armed with another tool to fight the coronavirus pandemic: a twice-daily pill that has been shown to reduce the risk of hospitalization and death among people infected with the ...

CNN — Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir. If authorization is granted, the drug ...